BioPorto Feed

2024-07-26 17:15:00 BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo

2024-07-17 17:50:49 Preliminary data suggests potential use beyond early AKI diagnosis for NGAL biomarker +0,68% | 1,60 MDKK

2024-07-11 17:15:00 Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury +5,20% | 5,95 MDKK

2024-07-04 17:54:36 Grant of Warrants -1,40% | 1,48 MDKK

2024-07-01 17:30:00 BioPorto confirms market acceptance of NGAL products with US standing order. +3,37% | 4,98 MDKK

2024-06-24 09:55:58 Managers’ transactions -1,91% | 4,74 MDKK

2024-06-24 09:52:56 Changes of number of shares and votes in BioPorto A/S -1,91% | 4,74 MDKK

2024-06-18 08:14:16 Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S. +13,64% | 9,44 MDKK

2024-06-17 19:04:16 BioPorto A/S initiates a private placement of 50,000,000 new shares at market price. +13,64% | 9,44 MDKK

2024-05-30 14:17:02 BioPorto A/S Appoints Chief Financial Officer +0,62% | 0,57 MDKK

2024-05-08 08:21:45 First Quarter 2024: Strong growth in US sales of The NGAL Test +11,35% | 7,10 MDKK

2024-05-07 13:10:30 BioPorto A/S Appoints President and CEO of BioPorto Inc. +0,14% | 1,68 MDKK

2024-05-02 13:53:23 BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting -0,46% | 0,38 MDKK

2024-04-30 15:46:18 Resolutions of Annual Geneal Meeting +3,68% | 0,45 MDKK

2024-04-23 19:20:26 Grant of warrants -0,16% | 0,22 MDKK

2024-04-10 13:22:25 BioPorto A/S Appoints Chief Legal Officer +1,11% | 0,51 MDKK

2024-04-05 15:46:51 New Board Candidate for the upcoming Annual Geneal Meeting +0,62% | 0,85 MDKK

2024-04-04 11:07:01 Notice convening the Annual General Meeting in BioPorto A/S -3,03% | 0,80 MDKK

2024-04-04 09:43:13 Correction: BioPorto Announces Annual Results for 2023 -3,03% | 0,80 MDKK

2024-04-04 08:29:12 BioPorto Announces Annual Results for 2023 -3,03% | 0,80 MDKK

2024-04-02 10:47:58 BioPorto A/S to Host Annual Earnings Webcast +3,82% | 2,31 MDKK

2024-04-02 07:54:00 BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer +3,82% | 2,31 MDKK

2024-02-22 07:31:41 BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026 -14,99% | 9,15 MDKK

2024-02-20 08:28:53 Roche Diagnostics and BioPorto expand collaboration +0,48% | 3,08 MDKK

2024-02-19 07:41:02 BioPorto A/S to host investor meetings on 22 February 2024 -0,48% | 1,72 MDKK

2024-01-09 19:42:40 BioPorto implements changes to the Executive Management. +5,02% | 9,92 MDKK

2023-12-09 18:12:45 Managers’ transactions -11,47% | 19,4 MDKK

2023-12-08 17:02:14 FDA Clears First Test to Identify Hospitalized Children at Risk for Acute Kidney Injury (AKI) -11,47% | 19,4 MDKK

2023-12-08 08:13:11 BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år +30,91% | 59,5 MDKK

2023-12-07 22:22:45 BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years +30,91% | 59,5 MDKK

2023-12-04 20:00:38 Resignation of Director -3,83% | 2,41 MDKK

2023-11-01 17:40:09 BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference +3,46% | 2,73 MDKK

2023-11-01 08:31:59 BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023 +2,07% | 2,63 MDKK

2023-10-31 15:17:05 BioPorto provides interim Q3 results and revised 2023 Financial Guidance. +7,89% | 1,86 MDKK

2023-10-20 18:14:30 BioPorto A/S to Host Third Quarter 2023 Earnings Webcast and Analyst Call -2,55% | 0,94 MDKK

2023-09-22 18:59:36 Grant of Warrants +0,12% | 0,39 MDKK

2023-09-19 15:16:28 BioPorto Initiates Search for new CFO as Neil Goldman Resigns -3,43% | 1,21 MDKK

2023-09-11 08:30:00 BioPorto Provides Update on NGAL Test Regulatory Pathway +9,41% | 2,08 MDKK

2023-08-28 17:32:10 BioPorto to Participate in Upcoming Investor Conferences -1,30% | 0,49 MDKK

2023-08-01 08:48:11 BioPorto Announces Interim Results for the First Six Months of 2023 -2,84% | 1,00 MDKK

2023-07-07 14:55:33 BioPorto A/S to Host Second Quarter 2023 Earnings Webcast and Analyst Call 0,00% | 0,55 MDKK

2023-06-29 08:11:19 BioPorto Announces Submission of Response to FDA Additional Information Letter +4,36% | 1,17 MDKK

2023-06-28 15:50:02 Managers’ transactions +1,59% | 0,21 MDKK

2023-06-23 07:49:24 BioPorto A/S announces completion of rights issue; total number of shares and voting rights -4,00% | 0,84 MDKK

2023-06-21 13:52:37 BioPorto A/S announces results of rights issue -4,12% | 2,13 MDKK

2023-06-09 15:38:20 BioPorto A/S to Webcast with HCA and Nordnet regarding the ongoing rights issue -0,70% | 0,98 MDKK

2023-05-30 17:27:39 BioPorto A/S initiates a rights issue with pre-emptive rights for its existing shareholders and proceeds of up to approximately DKK 59.4 million with approximately DKK 16.6 million pre-subscribed pursuant to advance commitments -14,41% | 2,48 MDKK

2023-05-23 20:02:58 Increase in share capital following exercise of warrants – Notice of changes in share capital and voting rights pursuant to section 32 of the Danish Capital Markets Act +0,89% | 0,19 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioPorto

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden